## Kone Kaniga

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9799288/publications.pdf

Version: 2024-02-01

1478505 1872680 6 239 6 6 citations h-index g-index papers 6 6 6 316 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EBioMedicine, 2018, 28, 136-142.	6.1	99
2	A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid. Journal of Clinical Microbiology, 2016, 54, 2963-2968.	3.9	42
3	A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing. Journal of Clinical Microbiology, 2016, 54, 2956-2962.	3.9	38
4	Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study. Journal of Clinical Microbiology, 2020, 58, .	3.9	29
5	Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective <i>In Vitro</i> Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates. Journal of Clinical Microbiology, 2022, 60, JCM0291920.	3.9	20
6	Epidemiological cut-offs for Sensititre susceptibility testing of Mycobacterium tuberculosis: interpretive criteria cross validated with whole genome sequencing. Scientific Reports, 2020, 10, 1013.	3.3	11